Obexelimab
Sponsors
Zenas Biopharma (USA) LLC, Zenas BioPharma (USA), LLC
Conditions
IgG4 Related DiseaseIgG4-Related DiseaseRELAPSING MULTIPLE SCLEROSISRelapsing Multiple SclerosisSystemic Lupus ErythematosusWARM AUTOIMMUNE HEMOLYTIC ANEMIAWarm Autoimmune Hemolytic Anemia
Phase 2
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Active, not recruitingNCT06559163
Start: 2024-09-17End: 2026-12-01Updated: 2026-08-18
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
Active, not recruitingNCT06564311
Start: 2024-08-26End: 2026-02-28Target: 93Updated: 2025-11-17
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Relapsing Multiple Sclerosis
RecruitingCTIS2024-512707-40-00
Start: 2024-11-07Target: 60Updated: 2025-11-14
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus
RecruitingCTIS2024-510584-37-00
Start: 2024-10-22Target: 91Updated: 2025-09-23
Phase 3
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Active, not recruitingNCT05662241
Start: 2023-01-09End: 2029-02-15Updated: 2026-02-04
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Active, not recruitingNCT05786573
Start: 2023-09-25End: 2026-08-31Target: 134Updated: 2025-06-25
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)
RecruitingCTIS2022-500718-24-00
Start: 2023-06-09Target: 105Updated: 2025-09-22
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A SAFETY AND DOSE CONFIRMATION RUN-IN PERIOD, TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (SAPHIARE)
CompletedCTIS2022-501005-12-00
Start: 2023-09-22End: 2025-08-27Target: 14Updated: 2025-04-15